- $192.28m
- $125.69m
- $129.42m
Chromadex Corp expected to post a loss of 3 cents a share - Earnings Preview
Brief: ChromaDex Corporation Q2 sales USD 20.323 million
Chromadex Corp reports results for the quarter ended in June - Earnings Summary
Chromadex Corp expected to post a loss of 4 cents a share - Earnings Preview
Brief: Chromadex Corp Files For Mixed Shelf Of Up To $125 Million – SEC Filing
Chromadex Corp reports results for the quarter ended in March - Earnings Summary
Brief: Chromadex Corp Reports First Quarter 2023 Financial Results
Chromadex Corp expected to post a loss of 5 cents a share - Earnings Preview
Brief: Chromadex Corp Reports Fourth Quarter and Fiscal Year 2022 Results
Chromadex Corp expected to post a loss of 2 cents a share - Earnings Preview
Brief: ChromaDex Announces Issuance Of New U.S. Patent On NRH, NARH
Brief: Chromadex Believes U.S. Court Of Appeals Decision Reg 807 Dartmouth Patent
Brief: ChromaDex Names Brianna Gerber As Chief Financial Officer
U.S. STOCKS ON THE MOVE-LegalZoom, Snail, metal miners
ChromaDex slips on FDA decision on flagship product ingredient
Brief: Chromadex Reports FDA's Conclusion That Nicotinamide Mononucleotide May Not Be Sold Or Marketed As Dietary Supplement In U.S.
Brief: Chromadex Corp Files For Of Up To 2.48 Million Shares Of Common Stock By Certain Selling Stockholders - SEC Filing
Chromadex Corp reports results for the quarter ended in September - Earnings Summary
Brief: Chromadex Corporation Reports Q3 2022 Financial Results